Linical Co., Ltd. is a Japan-based company mainly engaged in the contract research organization (CRO) business for drug companies. The Company operates in two businesses. The CRO segment is engaged in the provision of contract monitoring, quality management and consulting services for phase II and phase III in drug development processes. The Pharmaceutical Sales Support segment is engaged in provision of pharmaceutical sales support for medical institutions in the downstream market.

Employees

577

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-09-17	JP¥207.00	+1.47%	25,300
26-09-16	JP¥204.00	+0.49%	20,300
26-09-15	JP¥203.00	-0.49%	21,400
26-09-14	JP¥204.00	+0.49%	14,400
26-09-11	JP¥203.00	-0.49%	17,700

Delayed Quote Japan Exchange

More quotes

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Japan Exchange 02:30:00 2026-09-17 EDT			5-day change	1st Jan Change
207.00 ^JPY	+1.47%		+0.98%	-29.35%

08-14	Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2027	CI
08-14	Linical Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2027	CI

Market Cap	4.68B 30.01M 26.14M 24.74M 22.47M 41.99M 2.87B 42.19M 295M 114M 1.46B 113M 110M	P/E 2025	-13.4x	P/E 2026	-1.74x
Enterprise Value	1.72B 11.04M 9.62M 9.1M 8.27M 15.45M 1.06B 15.53M 108M 41.92M 537M 41.48M 40.56M	EV / Sales 2025	0.24x	EV / Sales 2026	0.33x
Free-Float	41%	Yield 2025	5%	Yield 2026	3.11%

08-14	Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2027	CI
08-14	Linical Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2027	CI
08-14	Linical Co., Ltd. Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
05-15	Linical Co., Ltd. Announces Consolidated and Non-Consolidated Asset Impairment for the Fourth Quarter of Fiscal Year Ended March 31, 2026	CI
03-18	Linical Co., Ltd. Revises Year End Dividend Guidance for the Fiscal Year Ending March 31, 2026, Payable on June 9, 2026	CI
03-18	Linical Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2026	CI
02-13	Linical Co., Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2025	CI
11-14	Linical Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2026	CI
25-05-15	Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2026	CI
25-05-15	Linical Co., Ltd. Provides Dividend Guidance for Year End of Fiscal Year Ending March 31, 2026	CI
25-05-15	Linical Co., Ltd. Announces Dividend for Year End of Fiscal Year Ended March 30, 2025, Payable on June 11, 2025	CI
25-02-14	Linical Co., Ltd. Revises Consolidated Results Forecast for the Fiscal Year Ending March 2025	CI
24-11-14	Linical Co., Ltd. Revises Consolidated Financial Guidance for the Year Ending March 31, 2025	CI

05-15	Linical : Notice Concerning Recording of Impairment Loss (Consolidated and Non-consolidated) and Loss on Valuation of Shares in Affiliates Non-consolidated), and Difference between Full-Year Consolidated Earnings Forecast and Actual Results	PU
02-13	Linical : Supplementary Information of Consolidated Financial Resultsfor the Nine Months ended December 31, 2025	PU
25-08-14	Linical : Supplementary Information of Consolidated Financial Resultsfor the Three Months ended June 30, 2025	PU
25-06-03	Linical : Notice of the 20th Ordinary General Meeting of Shareholders	PU
25-02-14	Linical : Supplementary Information of Consolidated Financial Results for the Nine Months ended December 31, 2024	PU

Linical Co., Ltd. Stock

Stocks

2183

JP3974530002

Biotechnology & Medical Research

Valuation: Linical Co., Ltd.

Chart: Linical Co., Ltd.

Latest news: Linical Co., Ltd.

Press Releases: Linical Co., Ltd.

Quotes and Performance

Price Extremes

Managers and Directors: Linical Co., Ltd.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

1 day	+1.47%
1 week	+0.98%
1 month	-2.82%
3 months	+0.98%
6 months	-33.87%
Current year	-29.35%

Manager	Title	Age	Since
Kazuhiro Hatano CEO	Chief Executive Officer	61	2024-05-31
Akihiro Takahashi DFI	Director of Finance/CFO	58	2007-03-31
Miguel Urrutia CTO	Chief Tech/Sci/R&D Officer	-	2026-06-30

Director	Title	Age	Since
Kazuhiro Hatano BRD	Director/Board Member	61	2024-05-31
Tomoko Nishimura BRD	Director/Board Member	59	2023-05-31
Yuichi Murakami BRD	Director/Board Member	69	2023-05-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LINICAL CO., LTD.	+1.47%	+0.98%	-39.47%	-70.55%	29.71M
LONZA GROUP AG	+1.23%	+1.30%	-0.69%	+9.57%	45.91B
IQVIA HOLDINGS INC.	+0.23%	+4.72%	+44.32%	+28.70%	44.25B
REVOLUTION MEDICINES, INC.	+0.52%	-3.15%	+349.53%	+536.73%	41.99B
BEONE MEDICINES AG	+1.55%	+3.41%	+6.40%	+69.19%	39.58B
CELLTRION, INC.	+1.75%	-1.53%	+12.22%	+41.11%	31.08B
MEDPACE HOLDINGS, INC.	-0.20%	+5.49%	+23.57%	+125.26%	17.21B
ASCENDIS PHARMA A/S	-3.49%	-8.49%	-	-	16.27B
EUROFINS SCIENTIFIC SE	+2.92%	+8.37%	+22.73%	+38.87%	14.96B
ICON PUBLIC LIMITED COMPANY	-2.45%	+2.41%	-3.16%	-35.49%	13.42B
Average	+0.46%	+1.33%	+46.16%	+82.60%	26.47B
Weighted average by Cap.	+0.77%	+0.68%	+72.22%	+122.86%

	2025	2026
Net sales	10.44B 66.99M 58.34M 55.22M 50.17M 93.73M 6.42B 94.19M 658M 254M 3.26B 252M 246M	8.66B 55.61M 48.44M 45.84M 41.65M 77.81M 5.33B 78.2M 546M 211M 2.71B 209M 204M
Net income	-539M -3.46M -3.01M -2.85M -2.59M -4.84M -331M -4.86M -33.97M -13.13M -168M -13M -12.71M	-3.33B -21.37M -18.61M -17.61M -16M -29.89M -2.05B -30.04M -210M -81.12M -1.04B -80.26M -78.48M
Net Debt	-4.71B -30.24M -26.34M -24.93M -22.65M -42.31M -2.9B -42.52M -297M -115M -1.47B -114M -111M	-2.96B -18.97M -16.52M -15.63M -14.2M -26.54M -1.82B -26.67M -186M -72M -923M -71.25M -69.66M

1 week	202	207
1 month	202	209
Current year	198	326
1 year	198	355
3 years	198	704
5 years	198	1,005
10 years	198	2,584